# NBE-Therapeutics

Source: https://onco.cc/companies/nbe-therapeutics/  
OnCo record `nbe-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NBE-Therapeutics, founded in Basel in 2012 and owned by Boehringer Ingelheim since 2020, builds antibody-drug conjugates that pair its own conjugation chemistry with a PNU-derived anthracycline payload, designed to kill tumour cells directly and to trigger a lasting immune response against the tumour. Its candidates are still moving towards the clinic.

## Summary

NBE-Therapeutics AG, founded in Basel in 2012, developed a next-generation antibody-drug conjugate platform for solid tumours combining its own conjugation technology, a PNU-derived anthracycline payload and antibody discovery capabilities. Its immune-stimulating ADC (iADC) concept aims for a long-lasting immuno-oncology effect in addition to direct cytotoxicity, with a pipeline of ADC candidates at various stages of development moving towards the clinic. The company became a wholly owned subsidiary of Boehringer Ingelheim in 2020 and in April 2025 opened a new ADC research and development centre in Basel that serves as a hub for Boehringer's ADC work.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Basel
- Type: biotech
- Website: https://nbe-therapeutics.com/

## Notes

- Boehringer Ingelheim's own acquisition release (reported elsewhere as up to EUR 1.18 billion, December 2020) is rendered client-side and returned no text to my fetches, so the deal value is omitted. Lead programme target (reported elsewhere as ROR1 for NBE-002) not stated on fetched pages.

## Sources

- Official website: https://nbe-therapeutics.com/
- Boehringer Ingelheim opens NBE R&D centre (states 2020 acquisition): https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune-stimulating antibody conjugate (ISAC)](https://onco.cc/technologies/immune-stimulating-adc/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nbe-therapeutics.json